| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 5 | +60.00% | +0.70% | +1.75% | -1.06% | -1.07% | — |
| 14d | 5 | +60.00% | +4.65% | +3.58% | +1.07% | -3.74% | — |
| 30d | 5 | +20.00% | +8.04% | +5.35% | +2.69% | +6.58% | — |
| 60d | 5 | +40.00% | +14.90% | +3.57% | -6.49% | -12.05% | — |
| 90d | 5 | +40.00% | +21.59% | +9.30% | +9.38% | +11.11% | — |
| 180d | 5(3 pending) | +50.00% | +12.13% | +3.63% | -7.54% | -7.54% | — |
| 1y | 5(5 pending) | — | — | — | — | — | — |
| 2y | 5(5 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| RAPP RAPPORT THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 3,308 | $42.17 | $139.5K | 150,914 | Jun 30, 2026 | Jul 1, 2026 ↗ | View → |
| RAPP RAPPORT THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 1,900 | $40.09 | $76.2K | 158,014 | Jun 30, 2026 | Jul 1, 2026 ↗ | View → |
| RAPP RAPPORT THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 3,792 | $41.39 | $157.0K | 154,222 | Jun 30, 2026 | Jul 1, 2026 ↗ | View → |
| RAPP RAPPORT THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 1,000 | $43.15 | $43.2K | 149,914 | Jun 30, 2026 | Jul 1, 2026 ↗ | View → |
| RAPP RAPPORT THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 2,839 | $28.55 | $81.1K | 159,914 | Mar 30, 2026 | Mar 31, 2026 ↗ | View → |
| RAPP RAPPORT THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 7,161 | $28.04 | $200.8K | 162,753 | Mar 30, 2026 | Mar 31, 2026 ↗ | View → |
| RAPP RAPPORT THERAPEUTICS, INC. | SALE Chief Operating Officer | 2,014 | $28.93 | $58.3K | 169,914 | Mar 5, 2026 | Mar 9, 2026 ↗ | View → |
| RAPP RAPPORT THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 132,000 | — | — | 132,000 | Feb 2, 2026 | Feb 4, 2026 ↗ | View → |
| RAPP RAPPORT THERAPEUTICS, INC. | SALE Chief Operating Officer | 5,000 | — | — | 105,407 | Nov 26, 2025 | Dec 1, 2025 ↗ | View → |
| RAPP RAPPORT THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 5,000 | $30.10 | $150.5K | 171,928 | Nov 26, 2025 | Dec 1, 2025 ↗ | View → |
| RAPP RAPPORT THERAPEUTICS, INC. | PURCHASE Chief Operating Officer | 5,000 | $1.80 | $9.0K | 176,928 | Nov 26, 2025 | Dec 1, 2025 ↗ | View → |
| RAPP RAPPORT THERAPEUTICS, INC. | SALE Chief Operating Officer | 5,000 | — | — | 110,407 | Sep 8, 2025 | Sep 10, 2025 ↗ | View → |
| RAPP RAPPORT THERAPEUTICS, INC. | PURCHASE Chief Operating Officer | 5,000 | $1.80 | $9.0K | 176,928 | Sep 8, 2025 | Sep 10, 2025 ↗ | View → |
| RAPP RAPPORT THERAPEUTICS, INC. | SALE10b5-1 10b5-1 plan | 5,000 | $38.33 | $191.7K | 171,928 | Sep 8, 2025 | Sep 10, 2025 ↗ | View → |
| RAPP RAPPORT THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 13,987 | — | — | 171,928 | Mar 3, 2025 | Mar 5, 2025 ↗ | View → |
| RAPP RAPPORT THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 129,000 | — | — | 129,000 | Feb 3, 2025 | Feb 4, 2025 ↗ | View → |
| RAPP RAPPORT THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 88,442 | — | — | 88,442 | Jun 6, 2024 | Jun 10, 2024 ↗ | View → |
| CYCN CYCLERION THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 135,000 | — | — | 135,000 | Jan 20, 2022 | Jan 24, 2022 ↗ | View → |
| CYCN CYCLERION THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 100,000 | — | — | 100,000 | Dec 9, 2021 | Dec 10, 2021 ↗ | View → |